Literature DB >> 15585085

Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals.

Jiri Mestecky1, Susan Jackson, Zina Moldoveanu, Lorie R Nesbit, Rose Kulhavy, Shirley J Prince, Steffanie Sabbaj, Mark J Mulligan, Paul A Goepfert.   

Abstract

This study was undertaken to resolve existing controversies with respect to the detection of IgA HIV-1-specific mucosal antibodies in infected individuals. External secretions, including tears, nasal, rectal, and vaginal washes, saliva, semen, urine, and sera were obtained from 50 HIV-1-infected individuals and 20 controls using collection procedures that minimize the irritation of mucosal surfaces. Levels of total and antigen (gp120 and gp160)-specific antibodies of the IgG and IgA isotypes were measured by assays that proved reliable in a large multicenter study: quantitative ELISA and chemiluminescence-enhanced Western blot analyses. Although the levels of total IgG and IgA were increased or remained unchanged in body fluids of HIV-1-infected individuals as compared to the controls, HIV-1-specific IgA antibodies were either absent or present at low levels even in secretions with characteristically high relative contents of total IgA vs. IgG (saliva, tears, and rectal and nasal washes). In these secretions, HIV-1-specific IgG antibodies dominated. In assessing levels and frequency of detection of IgG antibodies, both female and male genital tract secretions, urine, and nasal wash were preferable to parotid saliva and especially to rectal wash. External secretions contained IgG antibodies to gp160> gp120> gp41 and p24; when present, IgA antibodies were predominantly directed at gp160. Analyses of peripheral blood antibody-secreting cells (ASC) isolated from the same individuals paralleled these serological findings: gp160-specific IgG-secreting ASC were dominant. Therefore, in striking contrast to other mucosally encountered microbial infections, HIV-1 does not induce vigorous specific IgA responses in any body fluid examined or in ASC in peripheral blood.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15585085     DOI: 10.1089/aid.2004.20.972

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  63 in total

1.  Antiviral antibodies and T cells are present in the foreskin of simian immunodeficiency virus-infected rhesus macaques.

Authors:  Kristina Rothaeusler; Zhong-Min Ma; Huma Qureshi; Timothy D Carroll; Tracy Rourke; Michael B McChesney; Christopher J Miller
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

2.  Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women.

Authors:  Jiri Mestecky; Peter F Wright; Lucia Lopalco; Herman F Staats; Pamela A Kozlowski; Zina Moldoveanu; Rashada C Alexander; Rose Kulhavy; Claudia Pastori; Leonard Maboko; Gabriele Riedner; Yuwei Zhu; Terri Wrinn; Michael Hoelscher
Journal:  AIDS Res Hum Retroviruses       Date:  2010-11-22       Impact factor: 2.205

3.  Enhanced in vitro transcytosis of simian immunodeficiency virus mediated by vaccine-induced antibody predicts transmitted/founder strain number after rectal challenge.

Authors:  Sandeep Gupta; Poonam Pegu; David J Venzon; Johannes S Gach; Zhong-Min Ma; Gary Landucci; Christopher J Miller; Genoveffa Franchini; Donald N Forthal
Journal:  J Infect Dis       Date:  2014-05-21       Impact factor: 5.226

4.  Robust vaccine-elicited cellular immune responses in breast milk following systemic simian immunodeficiency virus DNA prime and live virus vector boost vaccination of lactating rhesus monkeys.

Authors:  Andrew B Wilks; Elizabeth C Christian; Michael S Seaman; Piya Sircar; Angela Carville; Carmen E Gomez; Mariano Esteban; Giuseppe Pantaleo; Dan H Barouch; Norman L Letvin; Sallie R Permar
Journal:  J Immunol       Date:  2010-11-01       Impact factor: 5.422

5.  An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo.

Authors:  Scott M Baliban; Amanda Michael; Berje Shammassian; Shikata Mudakha; Amir S Khan; Simon Cocklin; Isaac Zentner; Brian P Latimer; Laurent Bouillaut; Meredith Hunter; Preston Marx; Niranjan Y Sardesai; Seth L Welles; Jeffrey M Jacobson; David B Weiner; Michele A Kutzler
Journal:  Infect Immun       Date:  2014-07-14       Impact factor: 3.441

Review 6.  How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?

Authors:  Per Johan Klasse; Rogier W Sanders; Andrea Cerutti; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-20       Impact factor: 2.205

Review 7.  HIV infection and the gastrointestinal immune system.

Authors:  J M Brenchley; D C Douek
Journal:  Mucosal Immunol       Date:  2008-01       Impact factor: 7.313

Review 8.  Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection.

Authors:  Zdenek Hel; Elizabeth Stringer; Jiri Mestecky
Journal:  Endocr Rev       Date:  2009-11-10       Impact factor: 19.871

9.  Anti-HIV activity in cervical-vaginal secretions from HIV-positive and -negative women correlate with innate antimicrobial levels and IgG antibodies.

Authors:  Mimi Ghosh; John V Fahey; Zheng Shen; Timothy Lahey; Susan Cu-Uvin; Zhijin Wu; Kenneth Mayer; Peter F Wright; John C Kappes; Christina Ochsenbauer; Charles R Wira
Journal:  PLoS One       Date:  2010-06-29       Impact factor: 3.240

10.  HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits.

Authors:  Weifeng Xu; Paul A Santini; John S Sullivan; Bing He; Meimei Shan; Susan C Ball; Wayne B Dyer; Thomas J Ketas; Amy Chadburn; Leona Cohen-Gould; Daniel M Knowles; April Chiu; Rogier W Sanders; Kang Chen; Andrea Cerutti
Journal:  Nat Immunol       Date:  2009-08-02       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.